Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Charalambos Andreadis

Description

Summary

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.

Official Title

A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Details

Keywords

Mantle Cell Lymphoma, Lymphoma, Mantle-Cell Lymphoma, Immunological Antineoplastic Agents, Obinutuzumab, Antibodies, Immunoglobulins, Monoclonal Antibodies, Bispecific Antibodies, Pirtobrutinib, Glofitamab, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy

Eligibility

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
C. Babis Andreadis
ID
NCT06252675
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated